Focal Epilepsy Clinical Trial
Official title:
Novel DWI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery
This project will test the accuracy of a novel diffusion-weighted magnetic resonance imaging (DWMRI) approach using a deep convolutional neural network (DCNN) to predict an optimal resection margin for pediatric epilepsy surgery objectively. Its primary goal is to minimize surgical risk probability (i.e., functional deficit) and maximize surgical benefit probability (i.e., seizure freedom) by precisely localizing eloquent white matter pathways in children and adolescents with drug-resistant focal epilepsy. This new imaging approach, which will acquire a DWMRI scan before pediatric epilepsy surgery in about 10 minutes without contrast administration (and also without sedation even in young children), can be readily applied to improve preoperative benefit-risk evaluation for pediatric epilepsy surgery in the future. The investigators will also study how the advanced DWMRI-DCNN connectome approach can detect complex signs of brain neuronal reorganization that help improve neurological and cognitive outcomes following pediatric epilepsy surgery. This new imaging approach could benefit targeted interventions in the future to minimize neurocognitive deficits in affected children. All enrolled subjects will undergo advanced brain MRI and neurocognitive evaluation to achieve these goals. The findings of this project will not guide any clinical decision-making or clinical intervention until the studied approach is thoroughly validated.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | June 30, 2026 |
Est. primary completion date | June 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 3 Years to 19 Years |
Eligibility | Inclusion Criteria: 1. Subjects with drug-resistant focal epilepsy 1. Age 3-19 years. 2. Planned two-stage epilepsy surgery with subdural electrodes. 2. Healthy control subjects 1. Age 5-19 years. 2. No cognitive, motor, and/or language impairment or clinical elevations on a measure of behavioral problems. 3. Brain MRI interpreted as normal. Exclusion Criteria: For all subjects: 1. History of prematurity or perinatal hypoxic-ischemic event. 2. Hemiplegia on preoperative neurological examination by pediatric neurologists. 3. Dysmorphic features suggestive of a clinical syndrome. 4. Diagnosis of any pervasive developmental or psychiatric condition which clearly predates the onset of seizures, including autism spectrum disorder, tic disorders, obsessive-compulsive disorder. 5. MRI abnormalities showing massive brain malformation and other extensive lesions that likely destroyed the contralateral tracts and severely affected i) spatial normalization accuracy in advanced normalization tools (ANTs), mutual information (MI) between native T1- MRI of Geodesic SyN transform and template T1-MRI < mean-3*standard deviation of MI in the healthy control group and ii) parcellation accuracy in surface-matching-based deformable registration, target registration error (TRE) of fine tetrahedra mesh between native T1- MRI brain surface and template T1-MRI brain surface > mean-3*standard deviation of TRE in the healthy control group. 6. History of claustrophobia. 7. Unsuccessful MRI showing head motion > 2 mm in DWMRI (i.e., voxel size of DWMRI) which is evaluated by NIH TORTOISE DWMRI motion artifact correction package. 8. Subject who cannot speak English. |
Country | Name | City | State |
---|---|---|---|
United States | Wayne State University/Children's Hospital of Michigan | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Wayne State University | National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy of DCNN tract classification for detection of ESM-defined eloquent white matter pathways in healthy controls | Spatial overlap of DCNN tract classification (range: 0-100%, 0 indicating no overlap and 100% indicating complete overlap) will be evaluated between two different DWMRI scans of healthy controls: single-shell and generalized Q-sampling imaging (GQI) that are acquired on the same day. 14 ESM-defined eloquent pathways will be obtained using 14 DCNN tract classifications from the single-shell and GQI data, and the spatial overlap between single shell and GQI data (score: %) will be assessed per each pathway. | During procedure | |
Primary | Accuracy of DCNN tract classification for detection of ESM-defined eloquent area that will be acquired a month after the DCNN tract classification in children with drug-resistant epilepsy | Spatial overlap (range: 0-100%, 0 indicating no overlap and 100% indicating complete overlap) will be measured between cortical terminals of DCNN-classified white matter pathways and their ground truth data: ESM-defined eloquent areas that will be acquired a month after the DCNN tract classification. | 1 month | |
Primary | Accuracy of DCNN tract classification for prediction of eloquent white matter pathways providing no postoperative deficits that will be assessed at 1.5 years after surgery | Preservation (score: 1) vs. no preservation (score: 0) of preoperative DCNN-classified white matter pathways will be compared with presence (score: 1) vs. absence (score: 0) of postoperative deficits in primary motor, language, auditory, and visual functions that will be assessed at 1.5 years after surgery. | 1.5 years | |
Primary | Accuracy of DCNN tract classification combined with Kalman analysis to predict optimal margin balancing maximal seizure freedom and minimal functional deficits that will be assessed at 1.5 years after surgery | Preservation (score: 1) vs. no preservation (score: 0) of preoperative DCNN-Kalman filter predicted surgical margin will be compared with presence (score: 1) vs. absence (score: 0) of postoperative deficits and seizure freedom that will be assessed at 1.5 years after surgery. | 1.5 years | |
Primary | Strength of association between local efficiency of preoperative network and functional measure: full-scale IQ, verbal-IQ, non-verbal IQ, expressive language, receptive language, and motor function that will be assessed at 1.5 years after surgery | Local efficiency value (range: 0-1, 0 indicating no efficacy and 1 indicating the strongest efficacy) will be evaluated from full-scale IQ network, non-verbal IQ network, verbal IQ network, expressive language network, receptive language network, and motor network of preoperative DWMRI connectome data, respectively. Full-scale IQ (normal mean: 100, standard deviation: 15), verbal IQ (normal mean: 100, standard deviation: 15), non-verbal IQ (normal mean: 100, standard deviation: 15), expressive language score (normal mean: 50, standard deviation: 10), receptive language score (normal mean: 50, standard deviation: 10), and motor score (normal mean: 50, standard deviation: 10) will be also evaluated from neuro-psychology testing at 1.5 years after surgery. The correlation coefficient (range: 0-1, 0 indicating no correlation and 1 indicating complete correlation) will be evaluated between local efficiency and neuro-psychology score measured for each corresponding function. | 1.5 years | |
Primary | Strength of association between local efficiency of preoperative full-scale IQ network and epilepsy duration that will be assessed at the time of preoperative MRI (Hypothesis 2.2) | Full-scale IQ (normal mean: 100, standard deviation: 15) will be assessed at the time of preoperative MRI scan. It will be associated with local efficiency (range: 0-1, 0 indicating no efficacy and 1 indicating the strongest efficacy) of preoperative full-scale IQ network and epilepsy duration (range: 0-19 years) that will be assessed within 1 day of preoperative MRI scan. The correlation coefficient (range: 0-1, 0 indicating no correlation and 1 indicating a perfect correlation) will be evaluated between full-scale IQ and local efficiency of preoperative full-scale IQ network. | Within 1 day | |
Primary | Strength of association between local efficiency change of contralateral verbal-/non-verbal IQ network and verbal-/non-verbal IQ change that will be measured between 1 month before surgery and 1.5 years after surgery | Longitudinal change of local efficiency in contralateral verbal-/non-verbal IQ network (range: -1 - +1, -1 indicating a complete loss of local efficiency after surgery and +1 indicating a complete gain of local efficiency after surgery) will be measured from postoperative and preoperative DWMRI connectome data that will be measured between 1 month before surgery and 1.5 years after surgery, respectively. It will be then correlated with the longitudinal change of verbal/non-verbal IQ (range: -100 - +100, -100 indication a complete loss of verbal/non-verbal IQ after surgery and +100 indicating a complete improvement of verbal/non-verbal IQ after surgery) that will be measured between 1 month before surgery and 1.5 years after surgery. The correlation coefficient (range: 0-1, 0 indicating no correlation and 1 indicating a perfect correlation) will be calculated between two longitudinal changes. | 1.5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02245061 -
Cortical Excitability Assessment Using Paired Pulses
|
N/A | |
Terminated |
NCT05081518 -
A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy
|
Phase 1 | |
Withdrawn |
NCT05481905 -
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
|
Phase 2 | |
Completed |
NCT02208492 -
The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study
|
Phase 4 | |
Recruiting |
NCT04839601 -
RNS System RESPONSE Study
|
N/A | |
Completed |
NCT02898935 -
Improvement of the Accuracy of Spatial Representation of Invasive Exploratory Electrodes in Focal Epilepsy
|
||
Enrolling by invitation |
NCT05748236 -
The Efficacy and Safety of Lamotrigine Versus Carbamazepine in Focal Epilepsy
|
Phase 4 | |
Terminated |
NCT01724918 -
Lacosamide IV and EEG/EKG (LIVE) Study
|
Phase 2 | |
Completed |
NCT00855738 -
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
|
Phase 4 | |
Recruiting |
NCT06309966 -
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06210022 -
Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
|
||
Completed |
NCT01311440 -
Modified Atkins Diet Treatment for Adults With Drug-resistant Epilepsy
|
N/A | |
Terminated |
NCT03955432 -
Long-term Cardiac Monitoring in Epilepsy
|
N/A | |
Recruiting |
NCT06132893 -
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
|
Phase 2/Phase 3 | |
Recruiting |
NCT05100771 -
Optimized Volumetry in Radiology: Interest in Pediatric Brain MRI in the Exploration of Focal Epilepsy
|
||
Recruiting |
NCT04879433 -
Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy
|
||
Active, not recruiting |
NCT03916848 -
Novel Network Analysis of Intracranial Stereoelectroencephalography
|
N/A | |
Recruiting |
NCT05198882 -
Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy
|
Phase 1 | |
Recruiting |
NCT05981755 -
Breathing Rescue for SUDEP Prevention
|
N/A | |
Recruiting |
NCT03457961 -
Post-market Study of AMPA Receptor Antagonists for Epilepsy Patients in Hong Kong
|